Current Trials
ECHO Open to Accrual Clinical Trials
Updated: 5/10/2026
| Colorectal Metastatic SMT112-3005 (Summit) A Randomized, Active-Controlled, Double-Blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-Line Treatment of Metastatic Colorectal Cancer Lung V940-009 (Merck) A Phase 3 Randomized Double-Blind Study of Adjuvant Pembrolizumab with or without V940 in Participants with Resectable Stage II to IIIB (N2) NSCLC not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy (INTerpath-009). First Line Metastatic: Mirati 849-007 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation OSE210C302 (Artemia) A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ICI)-Artemia study Lymphoma/Leukemia BeiGene BGB-11417-303 A Phase 3 Randomized, Open-Label, Multicenter Study of Sontrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma MK-1026-011 (BELL WAVE-011) A Phase 3, Randomized Study to Compare Nemtabrutinib versus comparator (Investigator’s choice of Ibrutinib or Acalabrutinib) in participants with untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Solid Tumors RMC-APEX-103 Revolution Medicines, Inc. / A phase 1 / 2 Open-label, Multicenter Study of RAS(ON) inhibitors in combination with Ivonescimab with or without other Anti-Cancer Agents in patients with Solid Tumors All Cancers Bespoke Pan Cancer (Natera) Molecular Residual Disease (MRD) Detection and Monitoring in any cancer Supportive Care TP-CA-002 Tempus Gemini NSCLC Surveillance Study A longitudinal multiomic biomarker profiling study of patients with Non-Small Cell Lung Cancer (NSCLC) TP-CA-007 Tempus Aries A Biobank Registry Platform Study in Oncology CLIN-53 A Clinical Investigation on Improving Peripheral Neuropathy Induced by Chemotherapy with Advanced Compression Technology – A safety and efficacy study. Click here to watch a video about this trial. ***Studies to be opened*** Pfizer C6461006 AN INTERVENTIONAL PHASE 1b/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF-08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER Amgen 20240178 A Phase 3, Open Label, Multicenter,Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small- Cell Lung Cancer (DeLLphi-312) GSK DREAMM-15 A Phase 2, multicenter, open label, non-randomized study to evaluate the safety and efficacy of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15). |
For information on any of the above clinical trials, please contact: Dr. Spiro Curis scuris@echoct.com or (860) 886-8362, x251